Accurate1, non-invasive, continuous, wireless BP monitoring for neonatal and pediatric patients.
Learn MorePyrAmes platforms will provide options to continuously monitor blood pressure cNIBP for patients of all ages.
could benefit from BP monitoring but would not receive an arterial line because it is invasive and costly.2
50% of adults are affected by high blood pressure in the US, increasing their mortality rates.3
Raised blood pressure (BP) is responsible for 7.6 million deaths worldwide annually.4
cNIBP has the potential for early detection of conditions within preterm infants and adults.
PyrAmes has been awarded first place in the Early Commercialization Innovation Track in Bear Institute's second annual Pediatric Accelerator Challenge for Kids (PACK). The Bear Institute for Health Innovation is a partnership between Children's National Hospital and Oracle Health Cerner Corporation using HIT to improve the quality of care for children. The PACK awards recognize pediatric digital health innovations of start-up and early-stage companies working to bring innovative technologies to market for children.
SW National Pediatric Device Innovation Consortium recognizes Boppli™ platform for pediatric medical device innovation
CUPERTINO, CA and HOUSTON, TX, October 21, 2022 – The Southwest National Pediatric Device Innovation Consortium (SWPDC) awarded PyrAmes $25,000 for its Boppli platform— a non-invasive wearable sensor intended for neonatal ICU patients for continuous blood pressure monitoring with minimal skin contact, which serves as a potential alternative to arterial catheters and inflatable cuffs. The American Academy of Pediatrics (AAP) Section on Advances in Therapeutics and Technology (SOATT) annually recognizes pediatric device innovation.
A great need currently exists for medical devices designed specifically for children, which is most likely a result of economic, clinical, and regulatory challenges, as well as a lack of established mechanisms for joining pediatric device ideas with qualified individuals/programs and industry partners to create innovative and needed pediatric devices.
(more…)
PyrAmes’ novel Boppli™ device enables continuous, noninvasive blood pressure monitoring (cNIBP) for the hospital’s most fragile patients.
PROVIDENCE, RI and CUPERTINO, CA, September 13, 2022 — Sentec and PyrAmes have established a commercial partnership to bring Boppli, PyrAmes’ first-of-its-kind continuous noninvasive blood pressure device, to neonatal intensive care teams throughout the United States. Boppli has received Breakthrough Device Designation from the US Food & Drug Administration (FDA) and will be available after FDA 510(k) clearance, which is anticipated in the first half of 2023.
“We are excited to join forces with Sentec to commercialize our Boppli product,” said Xina Quan, PhD, Co-Founder and CEO of PyrAmes. “This important step enables us to bring our breakthrough technology to market and transform patient care. We believe Sentec is an ideal partner for us in the NICU, given our companies’ shared mission and focus on noninvasive technologies to enable better healthcare delivery.”In the neonatal intensive care unit (NICU) today, a baby’s blood pressure is either monitored continuously through an invasive arterial catheter or intermittently through cuff measurements. Both techniques present certain clinical challenges. The Boppli™ platform offers a new solution to overcome those challenges.
(more…)
2020 FDA Breakthrough Device Designation
Founding Member of CDC National Hypertension Control Roundtable
2020 SWPDC Pediatric Device Award, Member of SWPDC
2019 MedTech Innovator Accelerator & 2020 NCC-PDI MedTech Innovator Pediatric Accelerator
Exponential Medicine 2019 One to Watch Award